Vivoryon Therapeutics N.V. (AMS:VVY)
Netherlands · Delayed Price · Currency is EUR 1.120
-0.005 (-0.44%)
Aug 14, 2026, 5:35 PM CET
Vivoryon Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
33.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -3.62M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.76M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cabka | 191.03M |
| Morefield Group | 162.31M |
| Ctac N.V. | 121.14M |
| Ebusco Holding | 70.42M |
| Alumexx | 40.13M |
| Almunda Professionals | 31.49M |
| New Amsterdam Invest | 18.47M |
| Arcona Property Fund | 7.77M |
Vivoryon Therapeutics News
- 9 days ago - Vivoryon Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 9 days ago - Vivoryon Therapeutics Quarterly report: Q2 2026 - Filings
- 9 days ago - Vivoryon Therapeutics Earnings release: Q2 2026 - Filings
- 9 days ago - Vivoryon Therapeutics Slides: Q2 2026 - Filings
- 2 months ago - Vivoryon Therapeutics Quarterly report: Q1 2026 - Filings
- 4 months ago - Vivoryon Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 4 months ago - Vivoryon Therapeutics Annual report: Q4 2025 - Filings
- 4 months ago - Vivoryon Therapeutics Earnings release: Q4 2025 - Filings